Revive Therapeutics Ltd. 31R.F Stock
Revive Therapeutics Ltd. Price Chart
Revive Therapeutics Ltd. 31R.F Financial and Trading Overview
Revive Therapeutics Ltd. stock price | 0.0100 EUR |
Previous Close | 0.03 EUR |
Open | 0.03 EUR |
Bid | 0.03 EUR x N/A |
Ask | 0.05 EUR x N/A |
Day's Range | 0.03 - 0.03 EUR |
52 Week Range | 0.02 - 0.37 EUR |
Volume | 950 EUR |
Avg. Volume | 2.4K EUR |
Market Cap | 14.54M EUR |
Beta (5Y Monthly) | 0.190957 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.01 EUR |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
31R.F Valuation Measures
Enterprise Value | 7.11M EUR |
Trailing P/E | N/A |
Forward P/E | N/A |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | N/A |
Price/Book (mrq) | 0.8666667 |
Enterprise Value/Revenue | N/A |
Enterprise Value/EBITDA | -0.898 |
Trading Information
Revive Therapeutics Ltd. Stock Price History
Beta (5Y Monthly) | 0.190957 |
52-Week Change | -91.59% |
S&P500 52-Week Change | 20.43% |
52 Week High | 0.37 EUR |
52 Week Low | 0.02 EUR |
50-Day Moving Average | 0.04 EUR |
200-Day Moving Average | 0.12 EUR |
31R.F Share Statistics
Avg. Volume (3 month) | 2.4K EUR |
Avg. Daily Volume (10-Days) | 95 EUR |
Shares Outstanding | 353.56M |
Float | 357M |
Short Ratio | N/A |
% Held by Insiders | 2.48% |
% Held by Institutions | 2.63% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | June 30, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | June 30, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | 0% |
Gross Margin | 0% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | -28.92% |
Return on Equity (ttm) | -58.96% |
Income Statement
Revenue (ttm) | N/A |
Revenue Per Share (ttm) | N/A |
Quarterly Revenue Growth (yoy) | N/A |
Gross Profit (ttm) | N/A |
EBITDA | -7913904 EUR |
Net Income Avi to Common (ttm) | -7943900 EUR |
Diluted EPS (ttm) | -0.02 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 2.66M EUR |
Total Cash Per Share (mrq) | 0.007 EUR |
Total Debt (mrq) | 248.75K EUR |
Total Debt/Equity (mrq) | 2.1 EUR |
Current Ratio (mrq) | 0.797 |
Book Value Per Share (mrq) | 0.033 |
Cash Flow Statement
Operating Cash Flow (ttm) | -6996981 EUR |
Levered Free Cash Flow (ttm) | -4384062 EUR |
Profile of Revive Therapeutics Ltd.
Country | Germany |
State | ON |
City | Toronto |
Address | The Canadian Venture Building |
ZIP | M5C 1P1 |
Phone | N/A |
Website | https://www.revivethera.com |
Industry | Drug Manufacturers-Specialty & Generic |
Sector(s) | Healthcare |
Full Time Employees | N/A |
Revive Therapeutics Ltd., a life sciences company, focuses on the research and development of therapeutics for rare disorders and infectious diseases. The company offers cannabinoid pharmaceutical portfolio that focuses on rare inflammatory diseases. It is developing Bucillamine, which is in Phase 3 clinical study for the treatment of infectious diseases, including influenza and COVID-19; Psilocybin that is in Phase 1 clinical study for treating methamphetamine use disorder; Psilocin for the treatment of depression, anxiety, bi-polar disorder, bulimia and anorexia nervosa, and other diseases; and cannabidiol for treating autoimmune hepatitis and ischemia and reperfusion injury from organ transplantation. Revive Therapeutics Ltd. has research collaboration agreements with PharmaTher Inc. for the development of psilocybin in the treatment of cancer and the discovery of other uses of undisclosed psychedelic compounds; North Carolina State University for the development of a biosynthetic version of psilocybin based on a natural biosynthesis enzymatic platform; the University of California, San Francisco to explore the use of Bucillamine as a treatment for severe COVID-19; University of Health Sciences Antigua for the clinical research of psychedelics; and PharmaTher for the development of psilocybin microneedle patch. The company was incorporated in 2012 and is headquartered in Toronto, Canada.
Q&A For Revive Therapeutics Ltd. Stock
What is a current 31R.F stock price?
Revive Therapeutics Ltd. 31R.F stock price today per share is 0.0100 EUR.
How to purchase Revive Therapeutics Ltd. stock?
You can buy 31R.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Revive Therapeutics Ltd.?
The stock symbol or ticker of Revive Therapeutics Ltd. is 31R.F.
Which industry does the Revive Therapeutics Ltd. company belong to?
The Revive Therapeutics Ltd. industry is Drug Manufacturers-Specialty & Generic.
How many shares does Revive Therapeutics Ltd. have in circulation?
The max supply of Revive Therapeutics Ltd. shares is 605.19M.
What is Revive Therapeutics Ltd. Price to Earnings Ratio (PE Ratio)?
Revive Therapeutics Ltd. PE Ratio is now.
What was Revive Therapeutics Ltd. earnings per share over the trailing 12 months (TTM)?
Revive Therapeutics Ltd. EPS is -0.01 EUR over the trailing 12 months.
Which sector does the Revive Therapeutics Ltd. company belong to?
The Revive Therapeutics Ltd. sector is Healthcare.